ICCC
IMMUCELL CORPPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Mar 4 ImmuCell Corporation reported unaudited financial results for 2025,…
- R Mar 4 ImmuCell reported a 4.3% increase in 2025 product sales to $27.6 mil…
- R Apr 8 ImmuCell reported a 28.4% year-over-year increase in preliminary, un…
- R Apr 8 ImmuCell reported preliminary Q1 2026 sales of $10.4M, up 28.4% YoY,…
- B Jun 18 1 insider buy $76.0K at $9.50
- X Jul 31 Short interest jumps 25.3% to 17.6K
- X Aug 31 Short interest jumps 26.6% to 19.3K
- R Oct 13 ImmuCell announced preliminary, unaudited Q3 2026 product sales of $…
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $76.0K at an average $9.50. No open-market sales. Price is 8% above their cost.
- InstitutionsMIXED
Q2 2026: 1 added (0 new), 1 trimmed or exited.
- Short sellersCOVERING
Short interest −18.1% to 18.1K shares. 1.4 days to cover, ≈0.2% of shares.
- TrendUPTREND
2% above its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $229.7K |
| NORTHERN TRUST CORP | TRIM | $147.9K |
| MORGAN STANLEY | ADD | $1.4M |
| HighTower Advisors, LLC | ADD | $154.2K |
| UBS Group AG | TRIM | $7.0K |
| UBS Group AG | ADD | $9.9K |
| CITADEL ADVISORS LLC | TRIM | $138.9K |
| UBS Group AG | NEAR_EXIT | $6.3K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Jul 2020| Date | Firm | Rating |
|---|---|---|
| Jul 13, 2020 | Aegis Capital INITIATE | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 18, 2026 | te Boekhorst Paul Francis Olivier President and CEO | BUY | $76.0K |
| Apr 15, 2026 | Wainman Paul R Director | AWARD | 11,933 sh |
| Apr 15, 2026 | Basse Gloria F Director | AWARD | 11,933 sh |
| Apr 15, 2026 | Tomsche David Scott Director | AWARD | 11,933 sh |
| Apr 15, 2026 | Turner Kathy V Director | AWARD | 17,899 sh |
| Mar 20, 2026 | BRIGHAM MICHAEL F Director | EXERCISE | $146.0K |
| Mar 20, 2026 | BRIGHAM MICHAEL F Director | TAX W/H | $146.0K |
| Jan 27, 2026 | te Boekhorst Paul Francis Olivier President and CEO | AWARD | 109,500 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
5 filings · 1 press release · 3 bullish · 0 bearish · 2 mixed- BULLISH 8-KOct 13, 2026
ImmuCell announced preliminary, unaudited Q3 2026 product sales of $8.0 million, a 46% increase…
The 46% sales growth confirms strong commercial execution and market share gains, but the company acknowledges the comp was aided by depressed year-ago sales. Watch the Nov 13 full earnings call for…
- BULLISH 8-KMay 8, 2026
ImmuCell and Norbrook signed a Settlement Deed resolving claims from a 2019 agreement; Norbrook…
The $2M settlement boosts cash but is non-recurring. Monitor ImmuCell's next earnings call for any impact on working capital or reinvestment plans.
- BULLISH 8-KApr 8, 2026
ImmuCell reported a 28.4% year-over-year increase in preliminary, unaudited product sales for Q1…
The strong Q1 sales growth, particularly in the core Tri-Shield product line, signals effective execution of the company's strategy; traders should monitor the upcoming May 15 conference call for…
- MIXED PRESS-RELEASEApr 8, 2026
ImmuCell reported preliminary Q1 2026 sales of $10.4M, up 28.4% YoY, driven by a 38.5% surge in…
Traders should monitor the upcoming full financial release and conference call for clarity on gross margins, operating leverage, and whether domestic strength can offset international weakness…
All ICCC filing & press-release reports (6)
- 8-K reportOct 13, 2026
- 8-K reportMay 8, 2026
- 8-K reportApr 8, 2026
- PRESS-RELEASE reportApr 8, 2026
- 8-K reportMar 4, 2026
- PRESS-RELEASE reportMar 4, 2026